Microbiome analysis of gut microbiota in patients with colorectal polyps and healthy individualsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared fecal gut microbiota between 30 patients with colorectal polyps (86.7 percent tubular adenomas) and 30 healthy controls. The goal was to characterize microbiome alterations linked to these cancer precursor lesions.
How was it studied?
Fecal samples from all 60 prospectively enrolled subjects underwent 16S rRNA gene sequencing targeting the V3 to V4 region. Researchers compared alpha and beta diversity, taxonomic abundance, and used random forest and ROC analysis to test candidate biomarkers.
What did they find?
Beta diversity differed significantly between groups (p = 0.001), though alpha diversity did not. The polyp group had higher Bacteroides, Fusobacteria, and Proteobacteria, and higher Clostridium perfringens, Escherichia coli, Clostridium ramosum, and Ruminococcus gnavus. Bifidobacterium species and Faecalibacterium prausnitzii were lower in the polyp group. A random forest model distinguished groups with 0.88 accuracy, and Escherichia, Shigella, and Bacteroides showed ROC AUC values of 0.723, 0.712, and 0.705 respectively.
Why it matters
The findings show a structural imbalance in colorectal polyp patients, with fewer beneficial bacteria like Bifidobacterium and more potentially harmful taxa like E. coli and Fusobacteria. Escherichia, Shigella, and Bacteroides may serve as fecal biomarkers for early polyp detection, though the authors note single-center design and 16S sequencing depth limits, and call for multicenter validation.